Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK02 in refractory solid tumors
NCT05990920Phase 1Completed
- Sponsor
- NKGen Biotech
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNK02 in solid tumor and Treatment-resistant cancer, sponsored by NKGen Biotech. Primary endpoints: Dose-Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 8 weeks and 1 more. Started Aug 2023; status: completed.
02
Drugs
SNK02
03
Conditions
solid tumorTreatment-resistant cancer
Beyond the preview
Go deeper on NCT05990920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990920.